TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30586731

Group type: COMPARATOR
Intervention: USPIO enhancement in ballooning left ventricular myocardial segments
Number of subjects: 55

Group type: COMPARATOR
Intervention: USPIO enhancement in nonballooning left ventricular myocardial segments
Number of subjects: 55

Group type: COMPARATOR
Intervention: Serum interleukin-6 concentrations
Number of subjects: 55

Group type: COMPARATOR
Intervention: Serum chemokine (C-X-C motif) ligand 1 concentrations
Number of subjects: 55
Study: 30586733

Group type: EXPERIMENTAL
Intervention: Familial hypercholesterolemia mutation
Number of subjects: 2081

Group type: EXPERIMENTAL
Intervention: High polygenic score
Number of subjects: 2081

Group type: EXPERIMENTAL
Intervention: Mean untreated low-density lipoprotein cholesterol
Number of subjects: 2081
Study: 30586734

Group type: EXPERIMENTAL
Intervention: Noninvasive cardiac radioablation (25 Gy single fraction)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Noninvasive cardiac radioablation
Number of subjects: 19
Study: 30586740

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation patients over 12 months
Number of subjects: 52014

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation patients in the first month
Number of subjects: 52014

Group type: EXPERIMENTAL
Intervention: Predictive model for 1-month risk of death
Number of subjects: 52014
Study: 30586745

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 30586748

Group type: EXPERIMENTAL
Intervention: EHMRG7
Number of subjects: 1983

Group type: EXPERIMENTAL
Intervention: EHMRG7 combined with physician estimates
Number of subjects: 1983

Group type: EXPERIMENTAL
Intervention: EHMRG30-ST
Number of subjects: 1983

Group type: EXPERIMENTAL
Intervention: Physician-estimated risk combined with EHMRG30-ST
Number of subjects: 1983

Group type: EXPERIMENTAL
Intervention: Mortality rates at 7 days
Number of subjects: 1983

Group type: EXPERIMENTAL
Intervention: Mortality rates at 30 days
Number of subjects: 1983
Study: 30586749

Group type: EXPERIMENTAL
Intervention: Resting Full-Cycle Ratio (RFR)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Diastolic Pressure Ratio (dPR)
Number of subjects: 435

Group type: COMPARATOR
Intervention: Instantaneous Wave-Free Ratio (iFR)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: All resting pressure-derived physiological indexes (iFR, RFR, dPR)
Number of subjects: 435
Study: 30586751

Group type: EXPERIMENTAL
Intervention: PCDT with anticoagulation
Number of subjects: 391
Study: 30587228

Group type: EXPERIMENTAL
Intervention: Ankylosing spondylitis (AS) patients
Number of subjects: 210
Study: 30587230

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) program for 10 weeks
Number of subjects: 21
Study: 30587248

Group type: EXPERIMENTAL
Intervention: Methotrexate (61-84%)
Number of subjects: 15284

Group type: EXPERIMENTAL
Intervention: Etanercept (24%-61.8%)
Number of subjects: 15284

Group type: EXPERIMENTAL
Intervention: Glucocorticoids (16.7-42.1%)
Number of subjects: 15284
Study: 30587418

Group type: EXPERIMENTAL
Intervention: CT-MPI
Number of subjects: 97

Group type: COMPARATOR
Intervention: SPECT
Number of subjects: 97
Study: 30587541

Group type: EXPERIMENTAL
Intervention: Higher SES
Number of subjects: 623
Study: 30587911

Group type: EXPERIMENTAL
Intervention: Bifocal group (bilateral bifocal implantation)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trifocal group (bilateral trifocal implantation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (bilateral pseudophakic monofocal implantation)
Number of subjects: 0
Study: 30587935

Group type: EXPERIMENTAL
Intervention: Elbasvir/grazoprevir (EBR/GZR)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Sofosbuvir with pegylated interferon and ribavirin (SOF/PR)
Number of subjects: 255
Study: 30587957

Group type: EXPERIMENTAL
Intervention: Disease Awareness in COPD Questionnaire (DACQ)
Number of subjects: 0
Study: 30587996

Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole 2-3 mg/day
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Placebo (adjunct to ADT)
Number of subjects: 1171
Study: 30588103

Group type: EXPERIMENTAL
Intervention: Primary surgery with postoperative intensity-modulated radiotherapy (IMRT) delivering 65-70 Gy to CTV1 and 50-55 Gy to CTV2.
Number of subjects: 33
Study: 30588886

Group type: EXPERIMENTAL
Intervention: Chronic oral anticoagulant therapy (OACb)
Number of subjects: 10568
Study: 30589299

Group type: EXPERIMENTAL
Intervention: Socioaffective mental training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sociocognitive mental training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30589493

Group type: EXPERIMENTAL
Intervention: Alpha-1 antitrypsin deficiency with neonatal cholestasis
Number of subjects: 153

Group type: COMPARATOR
Intervention: Alpha-1 antitrypsin deficiency without neonatal cholestasis
Number of subjects: 153
Study: 30589495

Group type: EXPERIMENTAL
Intervention: Hypocoagulable TEG at baseline
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Coagulation Index
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Clot lysis
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Low protein C < 30%
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: ATIII
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: tPA
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Protein C activity <30%
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: tPA >20 ng/mL
Number of subjects: 243
Study: 30589773

Group type: EXPERIMENTAL
Intervention: Porcine-derived acellular peritoneal matrix
Number of subjects: 25
Study: 30589809

Group type: EXPERIMENTAL
Intervention: Nerve transfers
Number of subjects: 0
Study: 30589964

Group type: EXPERIMENTAL
Intervention: Bezafibrate add-on therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: UDCA alone
Number of subjects: 0
Study: 30590416

Group type: EXPERIMENTAL
Intervention: Transannular mitral bridge implantation
Number of subjects: 34
Study: 30590505

Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical model for network inference
Number of subjects: 0
Study: 30590564

Group type: EXPERIMENTAL
Intervention: Resting heart rate (RHR) categories: <60 bpm, 60≤65 bpm, 65≤70 bpm, 70≤75 bpm, 75≤80 bpm, ≥80 bpm
Number of subjects: 30937

Group type: EXPERIMENTAL
Intervention: RHR ≥80 bpm
Number of subjects: 30937

Group type: EXPERIMENTAL
Intervention: RHR categories
Number of subjects: 30937

Group type: EXPERIMENTAL
Intervention: Mean RHR above 75-80 bpm
Number of subjects: 30937
Study: 30590569

Group type: EXPERIMENTAL
Intervention: Saturated fat ingestion
Number of subjects: 38
Study: 30590576

Group type: EXPERIMENTAL
Intervention: Malaria infection before gestational age of 15 weeks
Number of subjects: 138
Study: 30590587

Group type: EXPERIMENTAL
Intervention: Prepregnancy free androgen index
Number of subjects: 2768

Group type: EXPERIMENTAL
Intervention: Fasting glucose
Number of subjects: 2768

Group type: EXPERIMENTAL
Intervention: Testosterone
Number of subjects: 2768

Group type: EXPERIMENTAL
Intervention: Fasting insulin
Number of subjects: 2768

Group type: EXPERIMENTAL
Intervention: Nonspecific features to PCOS
Number of subjects: 2768
Study: 30590586

Group type: EXPERIMENTAL
Intervention: T90 > 12 min
Number of subjects: 2840

Group type: EXPERIMENTAL
Intervention: T90
Number of subjects: 2840

Group type: EXPERIMENTAL
Intervention: ODI
Number of subjects: 2840

Group type: EXPERIMENTAL
Intervention: T90desaturation and T90non-specific
Number of subjects: 2840
Study: 30590596

Group type: EXPERIMENTAL
Intervention: Phylloquinone repletion (∼500 µg phylloquinone/d)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Phylloquinone depletion (∼10 µg phylloquinone/d)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Deuterated phylloquinone-rich collard greens (2H-phylloquinone) consumed on the 23rd day of each diet phase
Number of subjects: 63
Study: 30591285

Group type: EXPERIMENTAL
Intervention: Co-medications
Number of subjects: 1397

Group type: COMPARATOR
Intervention: Immunosuppressants
Number of subjects: 1397
Study: 30591290

Group type: EXPERIMENTAL
Intervention: INCRAFT AAA endograft
Number of subjects: 60
Study: 30591411

Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Drp1 signaling
Number of subjects: 0
Study: 30591548

Group type: EXPERIMENTAL
Intervention: DHEA 100 mg/day orally in combination with an aromatase inhibitor (AI)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: DHEA 100 mg/day orally
Number of subjects: 12
Study: 30591982

Group type: EXPERIMENTAL
Intervention: Tarextumab 5 mg/kg weekly
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tarextumab 10 mg/kg every other week
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tarextumab 7.5 mg/kg every three weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tarextumab 2.5 mg/kg weekly
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tarextumab 7.5 mg/kg every other week
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tarextumab at doses <2.5 mg weekly and 7.5 mg/kg every other and every three weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tarextumab
Number of subjects: 42
Study: 30592353

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1274

Group type: EXPERIMENTAL
Intervention: CRT-D-induced reverse remodelling
Number of subjects: 1274

Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 1274
Study: 30592431

Group type: EXPERIMENTAL
Intervention: Karaduman Chewing Performance Scale (KCPS)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Segmental Assessment of Trunk Control (SATCo)
Number of subjects: 119
Study: 30593271

Group type: EXPERIMENTAL
Intervention: Presumed malaria incidence
Number of subjects: 2723

Group type: EXPERIMENTAL
Intervention: Diarrhea incidence
Number of subjects: 2723

Group type: EXPERIMENTAL
Intervention: Acute respiratory infections (ARI) incidence
Number of subjects: 2723
Study: 30593513

Group type: EXPERIMENTAL
Intervention: Lapatinib (first-line treatment for patients with CNS metastasis at diagnosis)
Number of subjects: 977

Group type: EXPERIMENTAL
Intervention: Trastuzumab (first-line treatment for patients with CNS metastasis at diagnosis)
Number of subjects: 977

Group type: COMPARATOR
Intervention: CNS metastasis observed at or after diagnosis
Number of subjects: 977

Group type: COMPARATOR
Intervention: Quality of life
Number of subjects: 977
Study: 30593542

Group type: EXPERIMENTAL
Intervention: Long-term physical activity (exercise within calculated training pulse for 8 months)
Number of subjects: 98
Study: 30593776

Group type: EXPERIMENTAL
Intervention: Daily aspirin use
Number of subjects: 1698
Study: 30594245

Group type: EXPERIMENTAL
Intervention: Renal function assessment using the gold standard methodology.
Number of subjects: 9
Study: 30594474

Group type: EXPERIMENTAL
Intervention: LGE-CMR imaging
Number of subjects: 35
Study: 30595180

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 233
Study: 30595269

Group type: EXPERIMENTAL
Intervention: iFR-guided side-branch intervention
Number of subjects: 50
Study: 30595681

Group type: EXPERIMENTAL
Intervention: Serum Osteoprotegerin (OPG) levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-traditional, kidney-related cardiovascular risk factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional cardiovascular risk factors
Number of subjects: 0
Study: 30595963

Group type: EXPERIMENTAL
Intervention: Fetal surgery for OSB
Number of subjects: 21
Study: 30596402

Group type: EXPERIMENTAL
Intervention: Bendamustine with rituximab, etoposide and carboplatin (T(R)EC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: (R)ICE regimen (rituximab, ifosfamide, carboplatin, etoposide)
Number of subjects: 0
Study: 30596677

Group type: EXPERIMENTAL
Intervention: LivRelief Varicose Vein Cream
Number of subjects: 32
Study: 30596809

Group type: EXPERIMENTAL
Intervention: Higher exposures to regional NO2 (2-SD increase of 12.2 parts per billion)
Number of subjects: 3100

Group type: EXPERIMENTAL
Intervention: Higher exposures to acid vapor, EC, PM2.5, and non-freeway NOx
Number of subjects: 3100

Group type: EXPERIMENTAL
Intervention: Higher exposures to regional NO2, acid vapor, and EC
Number of subjects: 3100
Study: 30596880

Group type: EXPERIMENTAL
Intervention: Pyrotinib
Number of subjects: 15

Group type: COMPARATOR
Intervention: Afatinib
Number of subjects: 15

Group type: COMPARATOR
Intervention: T-DM1
Number of subjects: 15
Study: 30596882

Group type: EXPERIMENTAL
Intervention: Impulsivity
Number of subjects: 51368
Study: 30596901

Group type: EXPERIMENTAL
Intervention: Multifaceted infection prevention and control (IPC) bundle including IPC training, text message reminders, alcohol hand rub, enhanced environmental cleaning, and weekly bathing with 2% chlorhexidine gluconate.
Number of subjects: 2669

Group type: EXPERIMENTAL
Intervention: Multifaceted infection prevention and control (IPC) bundle
Number of subjects: 2669
Study: 30596974

Group type: EXPERIMENTAL
Intervention: Maternal primary infection in the first trimester
Number of subjects: 255

Group type: COMPARATOR
Intervention: Maternal primary infection in the second trimester
Number of subjects: 255

Group type: COMPARATOR
Intervention: Maternal primary infection in the third trimester
Number of subjects: 255
Study: 30596995

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 2400
Study: 30597027

Group type: EXPERIMENTAL
Intervention: qPCR for G. vaginalis and/or Atopobium vaginae above a threshold
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 16S ribosomal RNA gene sequencing
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High Shannon diversity index
Number of subjects: 120
Study: 30597300

Group type: EXPERIMENTAL
Intervention: Sample entropy (SampEn) in patients with GAD
Number of subjects: 85

Group type: COMPARATOR
Intervention: Sample entropy (SampEn) in healthy controls (HCs)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Relationship between spatial complexity and anxiety level
Number of subjects: 85
Study: 30597509

Group type: EXPERIMENTAL
Intervention: Prolonged dual anti-platelet therapy (DAPT)
Number of subjects: 16518

Group type: COMPARATOR
Intervention: Shorter duration DAPT
Number of subjects: 16518
Study: 30598343

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion (15-minute continuous infusion of native GLP-1 (7-36) NH)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 10
Study: 30598352

Group type: EXPERIMENTAL
Intervention: Thoracic sarcopenia assessment using CT-derived measurement of T12-level muscle area.
Number of subjects: 147

Group type: COMPARATOR
Intervention: Psoas sarcopenia measured at the L3 level using standard methods.
Number of subjects: 147
Study: 30598488

Group type: EXPERIMENTAL
Intervention: Solid organ transplantation
Number of subjects: 0
Study: 30598500

Group type: EXPERIMENTAL
Intervention: TKM-080301 (0.3 mg/kg to 0.75 mg/kg, maximum tolerated dose redefined at 0.6 mg/kg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: TKM-080301
Number of subjects: 43

Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 43
Study: 30598642

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg-equivalent dose regimens
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard anticoagulation
Number of subjects: 500
Study: 30598669

Group type: EXPERIMENTAL
Intervention: Enrolled individuals who signed a consent form and participated in the study.
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: Participants who declined consent after one or two years of enrollment.
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: Participants who refused specific procedures despite willingness to continue in the study.
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: Participants who refused blood tests due to fear.
Number of subjects: 863

Group type: EXPERIMENTAL
Intervention: Participants who declined complimentary exams.
Number of subjects: 863
Study: 30598732

Group type: EXPERIMENTAL
Intervention: Frequency of denture cleaning
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30598833

Group type: EXPERIMENTAL
Intervention: Physical Activity Intervention for Loneliness (PAIL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 0
Study: 30599768

Group type: COMPARATOR
Intervention: Plasma TMAO levels in patients with plaque rupture (3.33 μM; interquartile range: 2.48-4.57)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Elevated TMAO levels
Number of subjects: 211

Group type: COMPARATOR
Intervention: TMAO at a cutoff level of 1.95 μM
Number of subjects: 211
Study: 30600268

Group type: EXPERIMENTAL
Intervention: Genomic sequencing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carrier status information return policies
Number of subjects: 0
Study: 30600272

Group type: EXPERIMENTAL
Intervention: Diagnostic rapid genome sequencing
Number of subjects: 21
Study: 30600393

Group type: EXPERIMENTAL
Intervention: 8-foot-up-and-go test (8-FUGT)
Number of subjects: 34
Study: 30600654

Group type: EXPERIMENTAL
Intervention: Live zoster vaccine administered at 6-12 months after zoster illness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Live zoster vaccine administered at 1-5 years after zoster illness
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Live zoster vaccine
Number of subjects: 0
Study: 30601986

Group type: EXPERIMENTAL
Intervention: Modified dairy foods
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Milk
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Total dairy
Number of subjects: 904

Group type: EXPERIMENTAL
Intervention: Fluid dairy
Number of subjects: 904

Group type: COMPARATOR
Intervention: Dairy intakes
Number of subjects: 904
Study: 30602434

Group type: EXPERIMENTAL
Intervention: Web-based exercise intervention for 8 weeks
Number of subjects: 44
Study: 30602433

Group type: EXPERIMENTAL
Intervention: We Prevent intervention (two telehealth-delivered sessions: relationship skills session and CHTC session)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (one session only - CHTC session delivered via telehealth)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: We Prevent intervention
Number of subjects: 0
Study: 30602513

Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring (VR) used continuously for 14 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dapivirine Vaginal Ring (VR)
Number of subjects: 16
Study: 30602590

Group type: EXPERIMENTAL
Intervention: CT examinations for abdomen
Number of subjects: 2000000

Group type: EXPERIMENTAL
Intervention: CT examinations for chest
Number of subjects: 2000000

Group type: EXPERIMENTAL
Intervention: CT examinations for combined chest and abdomen
Number of subjects: 2000000

Group type: EXPERIMENTAL
Intervention: CT examinations for head
Number of subjects: 2000000
Study: 30602615

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus Docetaxel and Gemcitabine
Number of subjects: 13
Study: 30602785

Group type: EXPERIMENTAL
Intervention: Free recall drawing task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual saliency and meaning maps
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recall performance
Number of subjects: 0
Study: 30603376

Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (23vPPV) during pregnancy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 100
Study: 30603378

Group type: EXPERIMENTAL
Intervention: Dexamethasone as adjunctive treatment
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 300
Study: 30603797

Group type: EXPERIMENTAL
Intervention: Nintedanib (150 mg or 200 mg oral twice daily) and Bevacizumab (15 mg/kg once intravenously every 3 weeks)
Number of subjects: 18
Study: 30604078

Group type: EXPERIMENTAL
Intervention: Gut microbiota from SWL patients
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gut microbiota from PWL patients
Number of subjects: 18

Group type: COMPARATOR
Intervention: Gut microbiota from NSC patients
Number of subjects: 18
Study: 30604117

Group type: EXPERIMENTAL
Intervention: Genetic testing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Survey results
Number of subjects: 0
Study: 30605211

Group type: EXPERIMENTAL
Intervention: Avelumab, 10 mg/kg, every 2 weeks until disease progression, unacceptable toxic effects, or withdrawal from the study.
Number of subjects: 53
Study: 30605510

Group type: EXPERIMENTAL
Intervention: Inappropriate diagnosis in a ventricular arrhythmia zone with enabled therapy
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Inappropriate therapy
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Inappropriate shock
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: First 4 months following implantation
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Delay to next patient contact (DNPC)
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Inappropriate diagnosis recurrence
Number of subjects: 1882

Group type: EXPERIMENTAL
Intervention: Inappropriate therapy recurrence
Number of subjects: 1882
Study: 30605751

Group type: EXPERIMENTAL
Intervention: 3.6 Gy × 15 fx (DL1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 4.7 Gy × 10 fx (DL2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 7.1 Gy × 5 fx (DL3)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All dose levels (DL1, DL2, DL3)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Quality-of-life questionnaires
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: International Prostate Symptom Scores
Number of subjects: 24
Study: 30606052

Group type: EXPERIMENTAL
Intervention: Ticagrelor or Prasugrel
Number of subjects: 1497

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 1497
Study: 30606138

Group type: EXPERIMENTAL
Intervention: Transient ischemic attack (TIA)
Number of subjects: 577
Study: 30606144

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET-CT scan
Number of subjects: 85
Study: 30606165

Group type: EXPERIMENTAL
Intervention: Lung ultrasound score on admission
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Lactate level
Number of subjects: 175